Osteoporosis Is Associated with Deteriorating Clinical Status in Adults with Cystic Fibrosis
Table 5
Difference in baseline characteristics between osteoporotic and nonosteoporotic groups.
BMD within the normal range ()
Osteoporosis ()
p between groups
ppFEV1 (IQR)
70 (52–87)
44 (27–65)
<0.001
BMI kg/m2 (IQR)
22.5 (20.4–24.5)
19.6 (18.8–20.7)
<0.001
Age, years (IQR)
30 (24–39)
34 (25–47)
0.52
Males, n (%)
55 (52)
7 (37)
0.27
Females, n (%)
51 (48)
12 (63)
—
Pancreas insufficiency, n (%)
101 (95)
19 (100)
ns
Homozygous F508del, n (%)
74 (70)
16 (84)
0.38
CF-related diabetes, n (%)
43 (39)
8 (53)
0.03
CF-related diabetes, duration in years (IQR)
9 (6–16)
15 (10–25)
0.06
Chronic infection, n (%)
82 (77)
19 (100)
0.02
Steroid inhalation therapy, n (%)
52 (47)
3 (20)
0.06
Additional D3 supplementation, n (%)
36 (34)
11 (58)
0.05
Proton pump inhibitors, n (%)
41 (39)
2 (16)
0.07
ppFEV1: percent predicted forced expiratory volume in 1 second; BMI: body mass index; additional D3 supplementation: additional D3 supplementation in addition to routine supplementation; BMD: bone mineral density; IQR: interquartile range.
